Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.82 Insider Own0.40% Shs Outstand40.68M Perf Week4.19%
Market Cap890.08M Forward P/E- EPS next Y-2.85 Insider Trans3.83% Shs Float37.71M Perf Month-31.58%
Income-98.20M PEG- EPS next Q-0.76 Inst Own69.90% Short Float28.11% Perf Quarter-43.59%
Sales15.80M P/S56.33 EPS this Y35.60% Inst Trans5.55% Short Ratio7.10 Perf Half Y-21.91%
Book/sh6.05 P/B3.62 EPS next Y7.20% ROA-37.20% Target Price38.08 Perf Year-52.79%
Cash/sh5.54 P/C3.95 EPS next 5Y15.97% ROE-48.40% 52W Range12.12 - 55.61 Perf YTD7.41%
Dividend- P/FCF- EPS past 5Y-9.80% ROI-36.30% 52W High-60.65% Beta0.38
Dividend %- Quick Ratio6.60 Sales past 5Y-7.80% Gross Margin- 52W Low80.53% ATR1.50
Employees146 Current Ratio6.60 Sales Q/Q35.60% Oper. Margin- RSI (14)26.48 Volatility4.57% 6.35%
OptionableYes Debt/Eq0.01 EPS Q/Q43.20% Profit Margin- Rel Volume0.47 Prev Close21.57
ShortableYes LT Debt/Eq0.01 EarningsAug 04 Payout- Avg Volume1.49M Price21.88
Recom2.40 SMA20-16.67% SMA50-27.68% SMA200-23.16% Volume697,910 Change1.44%
22-Apr-14Reiterated Needham Buy $36 → $52
22-Apr-14Reiterated Deutsche Bank Hold $17 → $35
04-Mar-14Reiterated Canaccord Genuity Hold $25 → $27
21-Jan-14Upgrade Needham Hold → Buy $36
26-Nov-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
13-Nov-13Downgrade Needham Buy → Hold
13-Nov-13Downgrade Deutsche Bank Buy → Hold $71 → $17
12-Nov-13Reiterated FBR Capital Mkt Perform $48 → $20
30-Oct-13Initiated FBR Capital Mkt Perform $48
06-Sep-13Initiated Stifel Buy $51
22-Apr-13Initiated Needham Buy $57
04-Apr-13Initiated Robert W. Baird Outperform $63
03-Apr-13Initiated Robert W. Baird Outperform $63
08-Mar-13Reiterated Burrill Institutional Research Mkt Outperform $54 → $39
26-Nov-12Initiated Burrill Institutional Research Mkt Outperform $54
12-Sep-12Downgrade WBB Securities Hold → Sell $8 → $9
09-Aug-12Initiated WBB Securities Hold $8
09-Aug-12Downgrade WBB Securities Speculative Buy → Hold
19-Jul-14 09:12AM  Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About at Motley Fool
17-Jul-14 06:10PM  Your first trade for Friday at CNBC
05:59PM  [video] Fast Money Final Trade: GOOGL, MSFT & more at CNBC
08:12AM  The Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene Zacks
12-Jul-14 06:01PM  3 Stocks Crushed by the Market This Week at Motley Fool
11-Jul-14 04:33PM  3 Reasons Not to Worry About Sarepta Therapeutics Inc. at Motley Fool
04:00PM  Sarepta Plunges on Eteplirsen Study Results Zacks
09:49AM  Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT) at TheStreet
08:50AM  Today's Top Biotech Stocks to Watch: Johnson & Johnson and Sarepta Therapeutics at Motley Fool
07:03AM  Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session Zacks
10-Jul-14 05:45PM  [video] Stock Pops & Drops: COH, SRPT, CRAY, LB at CNBC -12.94%
04:26PM  Should Sarepta's Shares Be Tumbling? at Motley Fool
03:24PM  Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following Trial News Benzinga
02:10PM  Why Sarepta Therapeutics Inc. Stock Collapsed at Motley Fool
01:39PM  Investors Remain Confident in Sarepta After Shares Fall 20 Percent StockTwits
01:28PM  Sarepta price target lowered to $34 from $52 at Roth Capital theflyonthewall.com
12:38PM  Sarepta potential for near-term approval lower after update, says Piper Jaffray theflyonthewall.com
11:52AM  Janney Capital reiterates Sell rating on Sarepta at theflyonthewall.com
11:50AM  Sarepta story correction issued by Wall Street Journal at theflyonthewall.com
11:38AM  Down 17%: Is Sarepta a Bad News Buy? at Motley Fool
10:54AM  Sarepta shares defended at Needham at theflyonthewall.com
10:51AM  Why Sarepta Therapeutics (SRPT) Stock Is Plunging Today at TheStreet
10:09AM  Sarepta shares fall on muscular dystrophy drug data at CNBC
08:47AM  Sarepta Releases New Data, Facing A Sea Change At Regulators at Forbes
08:47AM  Sarepta Data Disappoints Wall Street As Expert Sees A Sea Change At FDA at Forbes
08:47AM  Sarepta Data Disappoints As Expert Sees A Sea Change At FDA at Forbes
08:32AM  Sarepta says on track to initiate several new studies of eteplirsen at theflyonthewall.com
08:31AM  Latest Sarepta Study Update Shows Greater Decline in Walking Ability at TheStreet
08:31AM  [video] Sarepta to file for approval of Eteplirsen at CNBC
08:30AM  Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy Business Wire
08-Jul-14 01:06PM  [video] Rough day for biotech at CNBC -7.29%
07:06AM  Sarepta Therapeutics (SRPT) Enters Oversold Territory Zacks
07-Jul-14 02:49PM  Sarepta's Monday Selloff on New (Old) Worries Addressed at TheStreet -7.36%
27-Jun-14 06:22AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders EDGAR Online
06:22AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders
24-Jun-14 08:10AM  Short Interest is Piling Up in Sarepta Therapeutics (SRPT) Stock, Time to Panic? Zacks
08:10AM  Short Interest is Piling Up in Sarepta Therapeutics (SRPT) Stock, Time to Panic?
18-Jun-14 04:30PM  Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference on June 24 Business Wire
04:30PM  Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference on June 24
09-Jun-14 12:59PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Sarepta Therapeutics Inc. Regarding Possible Breaches of Fiduciary Duty PR Newswire
12:59PM  SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Sarepta Therapeutics Inc. Regarding Possible Breaches of Fiduciary Duty
07-Jun-14 06:33PM  Why Wall Street is Betting Heavily Against Sarepta Therapeutics at Motley Fool
06:33PM  Why Wall Street is Betting Heavily Against Sarepta Therapeutics
06-Jun-14 05:11PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
05:11PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04-Jun-14 06:02PM  What You Need to Know About PTC Therapeutics' Promising DMD Drug at Motley Fool
06:02PM  What You Need to Know About PTC Therapeutics' Promising DMD Drug
03-Jun-14 09:21AM  Tuesdays Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology at Motley Fool
09:21AM  Tuesdays Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology
07:39AM  Prosensa to Seek U.S. Approval for DMD Drug at TheStreet
07:39AM  Prosensa to Seek U.S. Approval for DMD Drug
02-Jun-14 09:34AM  Sarepta Therapeutics Opens New Global Headquarters in Cambridge, Mass. Business Wire
09:34AM  Sarepta Therapeutics Opens New Global Headquarters in Cambridge, Mass.
31-May-14 11:56PM  Surprising MS Drug Approval: Time to Buy? at Motley Fool
11:56PM  Surprising MS Drug Approval: Time to Buy?
28-May-14 04:32PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online
04:32PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
27-May-14 01:12PM  3 Stocks That Soared Stupendously Last Week at Motley Fool
23-May-14 03:45PM  Sarepta to Acquire Manufacturing Facility Zacks
01:28PM  Isis Pharmaceuticals: 'The Best Pipeline in Biotech,' Potential Takeover Target at Barrons.com
12:37PM  PTC Muscular Dystrophy Drug Wins EU Panel Vote at Investor's Business Daily
12:04PM  PTC Muscular Dystrophy Drug Wins EU Panel Vote at Investor's Business Daily
10:25AM  [video] Ataluren drives PTC Therapeutics at CNBC
08:46AM  PTC Therapeutics Gets Warm Hug From Europe for DMD Drug; Prosensa Rises in Sympathy at TheStreet
07:12AM  [$$] Sarepta Looks Like a First-Mover at Barrons.com
22-May-14 11:36AM  Sarepta gearing for potential 2015 launch of eteplirsen, says Piper Jaffray at theflyonthewall.com
08:56AM  Today's Top Health Care Stocks to Watch: Celgene Corporation and Sarepta Therapeutics, Inc. at Motley Fool
08:32AM  Sarepta announces acquisition of Massachusetts manufacturing facillity at theflyonthewall.com
08:30AM  Sarepta Therapeutics Announces Agreement for Acquisition of Manufacturing Facility in Massachusetts Business Wire
07:07AM  Sarepta initiated with a Buy at Roth Capital at theflyonthewall.com
20-May-14 05:02PM  Sarepta Therapeutics' (SRPT) CEO Presents at UBS Global Healthcare Conference (Transcript) at Seeking Alpha
16-May-14 01:04PM  SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials
08:30AM  Sarepta Therapeutics to Present Company Overview at the UBS Global Healthcare Conference on May 20 Business Wire
14-May-14 06:17PM  Sarepta Therapeutics' (SRPT) CEO Chris Garabedian Hosts Sarepta DMD Development Program Update (Transcript) at Seeking Alpha
13-May-14 04:24PM  Sarepta Therapeutics' (SRPT) CEO Christopher Garabedian on Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
11:00AM  Sarepta Therapeutics Inc Conference Call to discuss DMD Development Program Update scheduled for 11:00 am ET today CCBN
11:00AM  Electro Scientific Industries, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:34AM  Sarepta Therapeutics Inc Conference Call to discuss DMD Development Program Update scheduled for 11:00 am ET today CCBN
12-May-14 12:24PM  Busy Days Ahead for Sarepta Therapeutics at Motley Fool
10-May-14 06:02PM  Sarepta Therapeutics's (SRPT) CEO Chris Garabedian Presents at Deutsche Bank Healthcare Conference (Transcript) at Seeking Alpha
09-May-14 03:03PM  Sarepta to hold a conference call at theflyonthewall.com
06:00AM  Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack at TheStreet
08-May-14 12:37PM  Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha -9.28%
11:48AM  Sarepta's Loss Widens 59% as it Prepares Eteplirsen For a New Drug Application Filing at Motley Fool
08:00AM  Sarepta Therapeutics Inc. Earnings Call scheduled for 8:00 am ET today CCBN
07:19AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
07:07AM  Sarepta reports Q1 EPS (55c) ex-items, consensus (80c) at theflyonthewall.com
07:07AM  Q1 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Sarepta Therapeutics Announces First Quarter 2014 Financial Results and Recent Corporate Developments Business Wire
06:56AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07-May-14 11:25AM  Why I Have Re-Entered Sarepta Therapeutics at Seeking Alpha
06-May-14 08:30AM  Sarepta Therapeutics to Present Company Overview at the 2014 Bank of America Merrill Lynch Healthcare Conference Business Wire
05-May-14 06:20PM  Biotech 101: Valuing Binary Events at Motley Fool
02-May-14 07:26AM  A Wall Street Transcript Interview with Brian Skorney, a Senior Analyst with Robert W. Baird & Co. Covering Biotechnology: Biotech Capital Inflows Reach Historic Highs Wall Street Transcript
29-Apr-14 08:35AM  Sarepta Therapeutics to Present Company Overview at the 2014 39th Annual Deutsche Bank Healthcare Conference Business Wire
08:30AM  Sarepta Therapeutics to Announce First Quarter 2014 Financial Results and Corporate Update on May 8, 2014 Business Wire
28-Apr-14 03:18PM  Cancer and Hepatitis C Treatment Breakthroughs Boost Pharma Stocks: Citigroup Investment Global Head of Healthcare Research & Analysis Andrew Baum, M.D. Interviews with the Wall Street Transcript Wall Street Transcript
08:30AM  Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on May 13, 2014 Business Wire
26-Apr-14 07:31AM  3 Stocks That Soared Stupendously This Week at Motley Fool
01:42AM  [$$] Why Apple Shares Could Keep Climbing at Barrons.com
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.